The European Medicines Agency (EMA) ruled on Wednesday that blood clots should be listed as side effects “Very rare” AstraZeneca’s vaccine against Covid-19. The MEA has established “A possible link with very rare cases of unusual blood clots with low blood platelets” , said the Amsterdam-based agency in a press release , considering however that the risk-benefit balance remains “Positive” .
titre du volet 1
This release accompanies a press conference to be attended by EAJ Executive Director Emer Cooke alongside other agency officials. It follows the suspension by several European countries of the use of the vaccine from the Anglo-Swedish laboratory due to the formation of rare blood clots, reported in several countries, among those vaccinated.
titre du volet 2
The ministers of health of the countries of the European Union (EU) must meet in the wake to take stock of the vaccine campaigns led by the Twenty-Seven. Marta Temido, the Minister of Health of Portugal, who currently holds the rotating EU Presidency, will lead this meeting which will begin “After the public announcement of the conclusions of the AEM pharmacovigilance risk assessment committee on the safety of the AstraZeneca vaccine” , announced a spokesperson for the Portuguese Presidency.